Pneumococcal Vaccines Market is expanding at a CAGR of 4.7% from 2018 to 2026

The latest market report published by Credence Research, Inc. “Pneumococcal Vaccines Market– Growth, Future Prospects, Competitive Analysis, 2018 – 2026,” the global pneumococcal vaccines market was valued at US$ 7,108.7 Mn in 2017 expanding at a CAGR of 5.1% from 2018 to 2026.

Browse the full report at https://www.credenceresearch.com/report/pneumococcal-vaccines-market

Market Insights

World Health Organization and U.S. Centers for Disease Control and Prevention (CDC) has recommended pneumococcal vaccination for all adults above age 65 and children below 2 years of age. Pneumococcal vaccine may or may not protect completely against pneumonia, however, it significantly reduces the risk of invasive pneumococcal diseases. Strong support by local government and private health organizations such as UNICEF and WHO have driven the demand for pneumococcal vaccines market. For instance, GAVI, a private and public alliance have contributed US$ 1.5 billion to the Advanced Market Commitment (AMC) for pneumococcal vaccines. GAVI has helped 60 countries to incorporate pneumococcal vaccines in their routine programs and immunized more than 143 million children globally in 2017. Moreover, Gavi has committed US$ 4 billion for pneumococcal vaccine by the 2021. Moreover, growing incidences of pneumococcal diseases worldwide is the driving factor for the growing demand for pneumococcal vaccines. Pneumonia is the leading reason for death in children accounting for more than 25% of deaths of children below age of 5. Growing burden of antibiotic resistance is one of the major challenges faced by the market.

Download Free PDF Sample Request: https://www.credenceresearch.com/sample-request/59482

In terms of vaccine type, pneumococcal conjugate vaccines (PCV) held the largest share in the global pneumococcal market owing to more number of PCV products present in the market i.e. PCV10 and PCV 13. Moreover, on-going clinical trials of PCV15 and PCV20 by Merck & Co., Inc. and Pfizer, Inc. respectively will further drive the growth of PCV market during the forecast period. The pneumococcal polysaccharide vaccine (PPSV) market is projected to grow at steady rate during the forecast period. In terms of geography, North America held the largest share in the global pneumococcal vaccines market in 2017. Increasing government funding and awareness programs in the region is fueling the market. For instance, pneumococcal conjugate vaccine (PCV) has been introduced in the routine immunization program to curb the burden of pneumococcus diseases. Europe holds a significant share in the market due to efficient vaccination programs in countries such as Italy, Netherlands, United Kingdom and other countries. Asia Pacific is expected to grow at fastest rate during the forecast period owing to high incidences of pneumococcal diseases. High investment and partnerships by pharmaceutical companies will further drive the market. For instance, in 2017 Pfizer was granted patent protection for company’s PCV in India. The key players operating in the market include Pfizer, Inc., Merck & Co. Inc., and GlaxoSmithKline plc.

Key Market Movements:

Growing burden of pneumococcal diseases worldwide and growing awareness regarding the same
Increasing government funding and introduction of effective vaccination programs to tackle the disease burden
High demand for pneumococcal vaccines in developing nations to drive the market
Strong support by WHO, UNICEF, GAVI and other private and public organization to fuel market growth

Table of Content
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Pneumococcal Vaccines Market Portraiture
2.2. Global Pneumococcal Vaccines Market, by Vaccine Type, 2017 (US$ Mn)
2.3. Global Pneumococcal Vaccines Market, by Product Type, 2017 (US$ Mn)
2.4. Global Pneumococcal Vaccines Market, by Geography, 2017 (US$ Mn)

Chapter 3. Pneumococcal Vaccines: Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global Pneumococcal Vaccines Market, by Key Players, 2017

Chapter 4. Global Pneumococcal Vaccines Market, by Vaccine Type, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Pneumococcal Conjugate Vaccine
4.3. Pneumococcal Polysaccharide Vaccine

Chapter 5. Global Pneumococcal Vaccines Market, by Product Type, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. 10-valent PCV
5.3. 13-valent PCV
5.4. 23-valent PPSV
5.5. Pipeline Analysis
5.5.1. Phase III Analysis
5.5.1.1. 15-valent PCV
5.5.1.2. 20-valent PCV
5.5.2. Tabular Representation of Phase I and Phase II Vaccines

Chapter 7. Company Profiles
7.1. Pfizer, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. GlaxoSmithKline PLC
7.3. Merck & Co., Inc.

Here you can get an updated sample on this report: https://www.credenceresearch.com/sample-request/59482

Our Blog: http://www.technicaltop.com/

About Us

Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we've manufactured a firm extraordinarily prepared to this task.

Media Contact
Name: Chris Smith
Address: 105 N 1st ST #429,
SAN JOSE, CA 95103 US
E-mail: sales@credenceresearch.com
Ph.: 1-800-361-8290
Website: http://www.credenceresearch.com
LinkedIn @ https://us.linkedin.com/company/credenceresearch

This release was published on openPR.